Inovio and GeneOne's MERS vaccine shows promise in phase 1 by Angus Liu Tuesday, July 3, 2018 Inovio's South Korean partner GeneOne plans to start a phase 1/2 study in South Korea in the third quarter.
Profectus, Emergent to work on Nipah vaccine under $25M CEPI deal by Angus Liu Friday, May 25, 2018 With MERS and Lassa fever projects funded, the outbreak-focused alliance is ready to put a check mark beside the third disease on its priority list.
CEPI signs $54.9M Lassa vaccine deal with HIV organization by Angus Liu Tuesday, May 22, 2018 The International AIDS Vaccine Initiative will use grant funding to develop a Lassa vaccine based on the VSV vector.
Inovio nets $56M CEPI grant for Lassa fever and MERS vaccines by Angus Liu Wednesday, April 11, 2018 The five-year grant will support Inovio through phase 2 development of DNA vaccines against Lassa fever and MERS.
CEPI grants Themis $37.5M for Lassa and MERS vaccines by Angus Liu Tuesday, March 6, 2018 The public-private vaccine coalition will support Themis' development of Lassa fever and MERS vaccines through phase 2.
Pharma joins in $1B outbreak prep group by Eric Sagonowsky Friday, January 20, 2017 Drugmakers have joined with governments and nonprofits around the world to launch an alliance that’ll take a proactive approach to potential deadly outbreaks.
